BOCH
BPMC

Blue Owl Capital Holdings’s Blueprint Medicines BPMC Stock Holding History

Blue Owl Capital Holdings’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-71,888
Closed -$6.63M – 45
2023
Q4 		$6.63M Buy
+71,888
New +$4.66M 1.59% 16

Other funds holding BPMC

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Blue Owl Capital Holdings's BPMC Position: Q1 2024 in Review

Blue Owl Capital Holdings sold out of Blueprint Medicines (BPMC) in Q1 2024, closing a stake of 71,888 shares — an estimated $6.63M sold.

Blue Owl Capital Holdings first reported a position in BPMC in Q4 2023 and held it in 1 quarter. The position peaked at $6.63M in Q4 2023. 283 funds tracked by Wall St. Rank hold BPMC as of Q1 2024.

  • Blue Owl Capital Holdings reported no remaining Blueprint Medicines position as of Q1 2024 after selling out during the quarter.
  • Blue Owl Capital Holdings sold 71,888 Blueprint Medicines shares in Q1 2024, an estimated $6.63M.
  • Blue Owl Capital Holdings first reported a position in Blueprint Medicines in Q4 2023 and held it in 1 quarter.
  • Blue Owl Capital Holdings's Blueprint Medicines position peaked at $6.63M in Q4 2023.
  • 283 funds tracked by Wall St. Rank held Blueprint Medicines as of Q1 2024.

Based on Blue Owl Capital Holdings's 13F filing for Q1 2024, filed 15 May 2024.